Infection in Solid Organ Transplant Recipients Clinical Trial
Official title:
Everyone Poops: An Evaluation of the Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
2.1. Study Objectives - Primary Objective(s) - Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant - Secondary Objective(s) - Identify the risk factors for recurrent CDI post-transplant in patients who were diagnosed with a CDI within one year prior to Solid Organ Transplant - Evaluate the impact of CDI on graft survival following Solid Organ Transplant
- Single center, retrospective cohort chart review study design - Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018 - Will analyze outcomes from April 1, 2014 to July 31, 2019 - Patient list will be generated in Epic and Meditech - All data will be obtained from Epic and Meditech - All data will be collected retrospectively after the patient is discharged from the hospital ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02260596 -
Respiratory Viral Infections in Pediatric Transplantation
|
N/A | |
Completed |
NCT01761435 -
Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination
|
Phase 3 | |
Completed |
NCT02382211 -
T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
|
||
Terminated |
NCT01761201 -
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
|
Phase 3 | |
Recruiting |
NCT05626530 -
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT01527591 -
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
|
N/A | |
Recruiting |
NCT02503982 -
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT01446445 -
Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
|
Phase 4 | |
Completed |
NCT01833416 -
Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients
|
N/A | |
Completed |
NCT01558037 -
Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients
|
N/A |